menu
    • menu
    [{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Idera Pharmaceuticals

    Menu

    Idera Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amster...

                            Details : Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Tilsotolimod (IMO-2125) has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive immune activation and may, in turn, contribute to tumor suppression ...

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 17, 2022

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Announces Tilsotolimod Updates

                            Details : Company announced clinical updates regarding IMO-2125 (tilsotolimod), its synthetic Toll-like receptor 9 agonist has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation.

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 14, 2021

                            Lead Product(s) : Tilsotolimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Announces Results from Illuminate-301 Trial of Tilsotolimod + Ipilimumab in Anti-PD-1 Re...

                            Details : ILLUMINATE-301 is a randomized, global, multi-center, open label Phase 3 trial comparing the efficacy of 8 mg intratumoral tilsotolimod in combination with 3 mg/kg ipilimumab versus 3 mg/kg ipilimumab alone in 481 patients with anti-PD-1 refractory advan...

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            March 18, 2021

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $20.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

                            Details : The Company plans to use the $10.0 million in cash proceeds to fund the completion of the ongoing ILLUMINATE-301 clinical trial and potential NDA filing of its lead product, tilsotolimod, for the treatment of anti-PD-1 refractory metastatic melanoma.

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $20.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037

                            Details : This new coverage expands protection of the first tilsotolimod method-of-use patent, which was directed to methods of treating metastatic melanoma and was issued in November 2019.

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

                            Details : ILLUMINATE-204 is a multi-center, two-arm phase 1/2 trial in patients with anti-PD-1 refractory advanced melanoma. The phase 1 portion of the trial tested the safety and efficacy of increasing doses of tilsotolimod in combination with either Yervoy®* or...

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 15, 2020

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $20.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

                            Details : The Company plans to use the initial proceeds and, if exercised, subsequent proceeds from the financing for the ongoing clinical development of tilsotolimod, its potential NDA filing and commercial launch, and for general corporate purposes.

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            July 15, 2020

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $20.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $20.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million

                            Details : The Company plans to use the proceeds to fund the completion, of the ongoing ILLUMINATE-301 clinical trial of its lead product, tilsotolimod, for anti-PD-1 refractory metastatic melanoma.

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            July 04, 2020

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $20.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals completes enrollment in registrational trial

                            Details : ILLUMINATE-301 is comparing the effectiveness of intratumoral tilsotolimod in combination with ipilimumab with ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma.

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 03, 2020

                            Lead Product(s) : Tilsotolimod,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Idera Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tilsotolimod,Ipilimumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Announces Final Clinical Safety And Efficacy Data From Illuminate-204 Trial In Advanced ...

                            Details : The combination regimen was generally well tolerated among the 62 patients receiving tilsotolimod at any dose in combination with Yervoy® in the ILLUMINATE-204 clinical trial.

                            Product Name : IMO-2125

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            April 21, 2020

                            Lead Product(s) : Tilsotolimod,Ipilimumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth